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Short and long term effects of antihypertensive therapy in the diabetic
rat. To compare the impact of differing antihypertensive regimens on
the development of renal injury, studies were performed in three groups
of moderately hyperglycemic diabetic rats, and one group of non-
diabetic control (C) rats. One diabetic group (DM) received no therapy
except insulin. The remaining diabetic groups received insulin and
either the angiotensin I converting enzyme inhibitor captopril (CAP), or
triple therapy (TRX) with reserpine, hydralazine and hydrochlorothia-
zide. CAP and TRX modestly and comparably lowered blood pressure.
At 6 to 10 weeks, DM rats exhibited elevation of the single nephron
glomerular filtration rate (SNGFR), due to elevations of the glomerular
capillary plasma flow rate (QA) and the glomerular capillary hydraulic
pressure (P0). in both DM/CAP and DM/TRX rats, blood pressure
reduction was associated with selective normalization of P0w, without
change in SNGFR or QA. In long-term (70 weeks) studies, DM rats
exhibited progressive albuminuria and marked glomerular sclerosis.
CAP limited albuminuria and injury to values even lower than those in
C rats, whereas TRX served only to delay, but not to prevent, the
increase in albuminuria. TRX reduced glomerular sclerosis, but was
less effective than CAP. At 70 weeks, CAP and TRX still reduced
systemic blood pressure; remained at normal levels with CAP
but was no longer controlled with TRX. These results confirm the
clinical observation that antihypertensive therapy slows diabetic gb-
merulopathy, but also suggest that CAP affords superior long-term
protection as compared to the other antihypertensive drug regimen
studied.
Microangiopathy is a major cause of morbidity and mortality
in diabetes mellitus, and progressive destruction of the renal
microcirculatory bed leads to end-stage renal disease in a
substantial percentage of Type I and Type 11 diabetic patients
[1]. The importance of hemodynamic factors in the progression
of diabetic glomerulopathy has been documented by observa-
tions that early diabetes is characterized by elevation of the
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glomerular filtration rate (GFR)' clinically [2, 3] as well as
experimentally [4—6], and that patients with the highest GFR
values early in the course of the disease are more likely to
progress to persistent proteinuria or overt diabetic glomerulop-
athy than are patients with more normal initial values for GFR
[3].
Further support for a hemodynamic basis of diabetic glomer-
ulopathy derives from studies of uninephrectomy [7, 8] or a high
protein diet [5], in which increases in the glomerular capillary
hydraulic pressure (PGC) and perfusion and filtration rates
accelerate the development of albuminuria and glomerular
structural injury [5]. Conversely, interventions which attenuate
these hemodynamic changes slow the development of glomer-
ular injury. Dietary protein restriction, which lowers the single
nephron (SN) GFR by reducing both the glomerular capillary
plasma flow rate (QA) and GC' affords structural protection in
this model [5]. Alternatively, selective reduction of PGC with
the angiotensin I converting enzyme inhibitor (CE!) enalapril
slows the development of injury even in the presence of
continued hyperfiltration and hyperperfusion [6], suggesting
that glomerular capillary hypertension is the crucial hemody-
namic determinant of progressive glomerular injury. Similar
findings have been documented in studies involving other
models of progressive glomerular injury 19—13]. Control of
glomerular hypertension may be dissociated from control of
Abbreviations used in this paper are: Al, angiotensin I; All,
angiotensin 11; A0, mean glomerular cross-sectional area; AP, mean
arterial pressure; BG, blood glucose; C, control; CAP, captopril; CEI,
converting enzyme inhibitor; DM, diabetes mellitus; GFR, glomerular
filtration rate; HbAIC, glycosylated hemoglobin; Hct, hematocrit; K1,
gbomerular capillary ultrafiltration coefficient; LKW, left kidney weight;
PAS, periodic acid Schiff; PRA, plasma renin activity; PRC, plasma
renin concentration; P.o, glomerular capillary hydraulic pressure; P,
mean glomerular transcapillary hydraulic pressure gradient; QA. gb-
merular capillary plasma flow rate; RA, RE, RT, afferent, efferent and
total arteriolar resistances; RAS, renin-angiotensin system; SHR, spon-
taneously hypertensive rat; SN, single nephron; SBP, systolic blood
pressure; STZ, streptozotocin; TRX, triple therapy (reserpine, hydrala-
zine, and hydrochiorothiazide); UaIbV, 24-hrurinary albumin excretion
rate; V0, mean glomerular volume; WKY, Wistar-Kyoto rat.
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systemic hypertension, in that therapy which lowers GCaf-
fords protection when systemic blood pressure is not lowered in
hypertensive models [11], or only modestly reduced in nor-
motensive animals [6, 14].
An important adverse consequence of diabetes is systemic
hypertension, which contributes to acceleration of diabetic
microangiopathic complications [I]. Clinical studies clearly
indicate that antihypertensive therapy slows the progression of
diabetic renal disease [15, 161. However, the existing studies do
not offer long-term comparisons among various antihyperten-
sive regimens. In experimental models of non-diabetic progres-
sive renal disease, effective antihypertensive control using the
triple therapy (TRX) regimen of reserpine, hydralazine and
hydrochlorothiazide reduces GC and slows the development of
renal injury in some models [13, 17], whereas this regimen fails
to control glomerular hypertension or to limit local injury in
others [10, 18, 19]. Preliminary short-term clinical studies in
non-diabetic renal disease suggest that CEI may offer a thera-
peutic advantage over conventional combination regimens [20—
22], presumably by a selective beneficial action to reduce
efferent arteriolar resistance and GC' but comparison studies
have not yet been performed in diabetic patients.
Accordingly, we sought to compare the early and long-term
glomerular hemodynamic and structural effects of equivalent
reduction in blood pressure with CE! and TRX in the moder-
ately hyperglycemic diabetic rat. The study was specifically
designed to determine the consequences of controlled reduction
in blood pressure to a predetermined level, using different
antihypertensive regimens, rather than to examine the effects of
specific doses of pharmacologic agents. This approach, adjust-
ing medication doses to achieve a desired level of blood
pressure control, is commonly used in the clinical treatment of
hypertension [15, 16, 20—22], and has revealed important differ-
ences in hemodynamic and morphologic consequences in pre-
vious studies of experimental renal disease [6, 10—14, 17—19].
Methods
Four groups of adult male Munich-Wistar rats, with initial
weights of 200 to 260 g, were studied. One group (C) served as
non-diabetic controls, and three groups were made diabetic by
intravenous tail injection of streptozotocin (STZ, Sigma Chem-
ical Co., St. Louis, Missouri, USA), 60 mg/kg body weight,
under Brevital anesthesia (50 mg/kg i.p.). Two days later,
induction of diabetes was confirmed by measurement of tail
blood glucose (BG) level using a reflectance meter (Miles Ames
Div., Miles Laboratories, Inc., Elkhart, Indiana, USA). Dia-
betic rats received daily evening injections of ultralente insulin
(Iletin I, Eli Lilly & Co., Indianapolis, Indiana, USA), in doses
individually adjusted to maintain BG levels between 200 and
400 mg/dl. BG levels were monitored at least once a week in all
diabetic rats, and occasional values were checked in non-
diabetic rats for comparison purposes. All rats were fed stan-
dard rat chow (Rodent Laboratory Chow 5001, Ralston Purina
Co., Richmond, Indiana, USA) ad libitum. The diet contained
the following composition by weight: protein, 23.4%; fat, 4.5%;
Na, 0.40%; Ca, 1.0%; Phos, 0.61%; K, 1.10%; kcal/g, 4.25.
One diabetic group (DM) received no therapy other than
insulin. A second diabetic group (DM/CAP) was treated with
insulin and with the CE! captopril (E.R. Squibb & Sons, Inc.,
Princeton, New Jersey, USA), administered in the drinking
water at a concentration of 0.75 to 1.0 g/liter. The third diabetic
group (DM/TRX) received insulin and an antihypertensive
triple therapy (TRX) regimen consisting of reserpine (5 mg/
liter), hydralazine (160 mg/liter) and hydrochlorothiazide (25
mg/liter; Sigma Chemical Co.) in the drinking water. Previous
studies have demonstrated the therapeutic efficacy of a modest
reduction in systemic blood pressure with CE! therapy in this
normotensive model [6]. !n the present study, doses of both
antihypertensive regimens were adjusted as needed to maintain
the systolic blood pressure in the range of 100 to 130 mm Hg,
representing a modest reduction below values seen in the DM
rats receiving only insulin. Extensive pilot testing established
that doses exceeding these levels resulted in excessive hypo-
tension (systolic blood pressure < 100mm Hg), while doses less
than those reported resulted in inadequate blood pressure
lowering (systolic blood pressure> 130 mm Hg). !n no circum-
stance did a dose differing from those reported by even 25
percent result in acceptable blood pressure control.
Some of the rats in each group (N = 8 to 11) underwent whole
kidney and glomerular hemodynamic studies at 6 to 10 weeks
after STZ injection. The long-term groups were followed with
monthly determinations of systolic blood pressure (SBP) by the
tail cuff method [23], and were placed in metabolic cages
bimonthly for determination of 24-hour urinary albumin excre-
tion rates (UaIbV). At 70 weeks, some of the rats underwent
measurement of glomerular hemodynamics, and 8 to 14 rats in
each group were sacrificed for morphologic examination.
Separate groups of comparably treated rats were decapitated
and trunk blood collected in EDTA after 6 to 10 weeks of
diabetes for determination of plasma renin concentration
(PRC).
Micropuncture studies
Following BG measurement, rats were anesthetized with
Inactin (100 mg/kg i.p.) and placed on a temperature-regulated
table. The left femoral artery was catheterized, and a baseline
collection of blood was obtained for measurement of hematocrit
(Hct), inulin "blank", and plasma sodium and potassium levels.
This arterial catheter was used for subsequent periodic blood
sampling and estimation of mean arterial pressure (AP) via an
electronic transducer connected to a direct-writing recorder.
After tracheostomy, venous catheters were inserted for infu-
sions of inulin and plasma. Intravenous infusions of rat plasma,
and 10% inulin solution in 0.9% NaCI, were started at rates of
6.0 and 1.2 mI/hr. respectively. The left ureter was catheterized
for urine collection, and the left kidney exposed and suspended
on a lucite holder, with its surface illuminated and bathed with
isotonic saline.
Since the plasma volume of rats prepared for micropuncture
is reduced by —20% [24], euvolemia was maintained using the
following protocol. !soncotic rat plasma was infused at 6 mI/hr
in a total amount equal to 1% of the body weight, followed by
a reduction in infusion rate to 1.6 mI/kg/hr. to maintain the Hct
constant. Diabetic rats received extra saline to match the
excessive urinary losses during the procedure.
For calculation of SNGFR, exactly timed samples of tubule
fluid were collected for determination of flow rate and inulin
concentration. Samples of efferent arteriolar blood were ob-
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tamed for determination of protein concentration. Coincident
with these collections, arterial blood was obtained for determi-
nation of Hct and plasma concentrations of inulin and protein,
and 10 to 20 minute urine collections were obtained for deter-
mination of flow rate and inulin concentration. These measure-
ments permitted calculation of GFR (inulin clearance) by stan-
dard formulas. Time-averaged hydraulic pressures were
measured in surface glomerular capillaries, proximal tubules,
and efferent arterioles with a servo-null micropipette transducer
system (Instrumentation for Physiology and Medicine, San
Diego, California, USA). Colloid osmotic pressure of plasma
entering and leaving glomerular capillaries was estimated from
values for protein concentration in femoral arterial (represent-
ing afferent arteriolar) and efferent arteriolar plasma using the
equation derived by Deen, et al [25]. These estimates of pre-
and post-glomerular plasma protein concentration permit cal-
culation of SN filtration fraction, glomerular capillary ultrafil-
tration coefficient (Kr), and afferent and efferent arteriolar blood
flow rates and resistances, using equations previously described
[25]. Continued hyperglycemia was confirmed by repeat BG
measurement at the end of the procedure, at which time the left
kidney was weighed, and blood obtained for determination of
glycosylated hemoglobin (HbA1).
Morphology
Kidneys were perfused at the measured systolic arterial
pressure for two to three minute with 1.25% glutaraldehyde in
0.1 M sodium cacodylate buffer (pH 7.4). After perfusion
fixation, the weights of both kidneys were recorded, and two
midcoronal slices of 2 to 3 mm thickness were processed for
light microscopic examination. Three micrometer-thick paraffin
sections were stained with hematoxylin and eosin and by the
periodic acid Schiff (PAS) reaction. The extent of glomerular
damage was determined on PAS-stained slides by counting on
two coronal sections all glomerular profiles with segmental or
global collapse of capillaries with or without associated hyalin
deposition and adhesion of the tuft to Bowman's capsule. On
average, 472 glomeruli per animal were evaluated, and the
extent of glomerular sclerosis was expressed as the percentage
of glomeruli with sclerotic lesions.
-
The average glomerular tuft volume (V0)foreach animal was
determined by the procedure described by Weibel [26]. For this
purpose, the mean glomerular random cross-sectional area (AG)
was determined on 50 systematically sampled glomerular tuft
profiles by point counting at a final magnification of 200 x using
a 361-point ocular grid covering a 369,664 m2 microscopic
field. VG was then calculated as V0 = (/31K)(A0)312, where /3 =
1.38 and K = 1.1 are shape and size distribution coefficients [26,
27].
Analytical
The volume of fluid collected from individual proximal tu-
bules was estimated from the length of the fluid column in a
constant bore capillary tube of known internal diameter. The
tubule fluid inulin concentration was measured by a micro-
fluorescence method [28]. Inulin concentrations in plasma and
urine were measured using a macro-anthrone method [29].
Protein concentrations were determined using a fluorometric
method [30]. Urinary albumin concentration was measured by
radial immunodiffusion [31], Glycosylated hemoglobin was de-
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Fig. 1. Body weight. Serial values for body weight in non-diabetic
control rats (C, N = 15), diabetic rats (DM, N 14), and diabetic rats
treated with captopril (DM/CAP, N = 10) or triple therapy (DM/TRX,N = 12). At all points after the first, all diabetic groups weighed
significantly less than did C rats, but body wt values did not differ
among diabetic groups. Values are means SEM.
termined by affinity column chromatography (Glyco-Gel B,
Pierce Chemical Co., Rockford, Illinois, USA) [321. Plasma
sodium and potassium levels were measured by flame photom-
etry. PRC was determined by incubating 0.1 ml of rat plasma
with 0.1 ml rat anephric plasma and 0.4 ml of 0.2 M maleate
buffer, pH 6.0 at 37°C for one hour. Appropriate dilutions of rat
plasma samples were made using Tris buffer. The generation of
angiotensin I was then determined by radioimmunoassay using
commercially available reagents (New England Nuclear, Bos-
ton, Massachusetts, USA).
Statistical
Statistical analysis was performed by one-way analysis of
variance followed by computation of modified t values for six
preplanned pairwise comparisons according to the method of
Bonferroni [33]. Statistical significance was defined asP < 0.05.
Values for PRC, UaIbV, and glomerular sclerosis, which were
not normally distributed, were subjected to log transformation
for statistical analysis. All values represent means SEM.
Results
General
All diabetic rats failed to gain weight during the first month of
diabetes, thus resulting in slightly slower growth than in non-
diabetic C rats (Fig. 1). Thereafter, rates of weight gain were
fairly comparable in all groups, though body weights in the
diabetic groups never reached those of C rats. Comparable
hyperglycemia was maintained in all diabetic groups (Fig. 2).
Values for awake systolic blood pressure (Fig. 2) were slightly
elevated in DM rats, averaging 151 2 mm Hg over the 70 week
course, as compared to an average value of 125 1 mm Hg in
C rats (P < 0.05). In both DM/CAP (120 2 mm Hg) and
DM/TRX (118 2 mm Hg) groups, values for SBP were
modestly but significantly lower than in DM rats; at no time did
values differ between CAP and TRX. Values for PRC deter-
mined after 6 to 10 weeks of diabetes are depicted in Table 1. In
DM rats, values for PRC were somewhat depressed as com-
pared to non-diabetic rats (P < 0.05). Inhibition of converting
enzyme in DM/CAP rats was confirmed by marked elevation of
PRC (P < 0.05 vs. all other groups). In DM/TRX rats, stimu-
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Fig. 2. Blood glucose and systolic blood pressure. Serial values for
blood glucose (BG) and systolic blood pressure (SBP) in non-diabetic
control rats (C), diabetic rats (DM), and diabetic rats treated with
captopril (DM/CAP) or triple therapy (DM/TRX). All diabetic groups
exhibited comparable hyperglycemia over time, with BG values con-
sistently exceeding those in C rats, but not differing among diabetic
groups. Values for SBP were modestly but significantly elevated in DM
rats as compared to non-diabetic C rats at all time points, while SBP
was significantly and comparably lowered in both DM/CAP and DM1
TRX rats as compared to group DM. Values are means SEM; N as per
Fig. I.
lation of the plasma renin-angiotensin system was also appar-
ent, with values for PRC above the normal range, though lower
than in the DM/CAP rats (P < 0.05 vs. all other groups).
Insulin requirements did not differ among diabetic groups.
Random measurements indicated that food and water intake
were supranormal in all diabetic groups, but did not differ
among them. Intakes varied from day to day in all groups; the
approximate average range of daily intakes was 15 to 20 g food
and 15 to 30 ml water/day for control rats, and 35 to 50 g food
and 70 to 125 ml water/day for the diabetic groups.
Early micropuncture experiments
Mean values for body weight, left kidney weight (LKW), BG,
HbAC, Hct, A, whole kidney GFR, and plasma sodium and
potassium levels at 6 to 10 weeks of diabetes, and in weight-
matched non-diabetic control rats, are summarized in Table 2.
Values for body wt did not differ among the groups. Increased
kidney weight was evident in all diabetic groups, with signifi-
cant and equivalent elevations of LKW as compared to C rats.
Hyperglycemia, as evidenced by elevation of both BG and
HbAIC levels, was present in all diabetic groups. Hematocrit
was slightly lower in both DM/CAP and DM/TRX groups than
in DM rats, but no diabetic group was significantly different
from controls. Values for AIwere equivalent in C and DM rats,
whereas AP was comparably reduced in rats receiving CAP or
TRX (both P < 0.05 vs. DM). Diabetic rats exhibited whole
kidney hyperfiltration, with values in both treated groups being
slightly though not significantly lower than those in DM rats,
and not different from one another. Values for plasma sodium
concentration were comparable in the three diabetic groups.
Plasma potassium levels tended to be slightly elevated in
Group
Body wt
g
BG
mg/dl
PRC
ng Al/mi/hr
C 285 II 89 7 10.0 1.5
(N= II)
DM 260 8 286 8 4.9 o.8
(N = 11)
DM/CAP 261 6 322 l0 3537 634a.b
(N =7)
DM/TRX 276 12 305 l9 46.3
(N = 7)
Abbreviations are: C, non-diabetic control; DM, diabetic; DM/CAP,
DM + captopril; DMITRX, DM + triple therapy; Body wt, body weight;
BG, blood glucose; PRC, plasma renin concentration; Al, angiotensin I.
Values are means SEM.
P < 0.05 vs. C
b P < 0.05 vs. DM
c P < 0.05 vs. DM/CAP
DM/CAP rats, and were statistically lower in DM/TRX groups
than in the other diabetic groups.
Mean values for SNGFR, and the pressures, flows, and
resistances governing glomerular ultrafiltration are summarized
in Table 3. As in previous studies [4—6], the moderately hyper-
glycemic diabetic rats exhibited single nephron hyperfiltration;
neither CAP nor TRX affected the supranormal SNGFR values.
Values for SN filtration fraction were slightly higher in DM rats,
and lower in both DM/CAP and DM/TRX rats, though these
differences did not reach statistical significance. All diabetic
rats exhibited comparable levels of glomerular capillary hyper-
perfusion, with comparable elevations of QA as compared to
controls. In DM rats, glomerular hyperperfusion was accompa-
nied by glomerular capillary hypertension; both the glomerular
capillary hydraulic pressure (PGC) and the glomerular transcap-
illary hydraulic pressure gradient (P) were elevated signifi-
cantly. Diabetes induced primarily afferent arteriolar vasodila-
tation, so that both afferent arteriolar resistance (RA) and the
ratio of afferent arteriolar to total arteriolar resistance (RA/RT)
were reduced. In DM/CAP and DM/TRX groups, afferent
arteriolar vasodilatation was offset by concomitant efferent
arteriolar vasodilatation, so that values for RA/RT were normal-
ized, and values for GC and were maintained at levels
comparable to those seen in non-diabetic controls. Values for
afferent and efferent protein concentrations and colloid osmotic
pressures did not differ significantly. Values for K, the glomer-
ular capillary ultrafiltration coefficient, were numerically
though not statistically lower in the DM rats, whereas they were
maintained at normal levels in both DM/CAP and DM/TRX
rats; only the difference between DM and DM/TRX achieved
statistical significance. Thus, all diabetic groups exhibited sin-
gle nephron hyperfiltration and hyperperfusion. In the DM rats,
elevated SNGFR resulted from elevations in both QA and GC,
while hyperfiltration in both treated groups resulted from ele-
vation of QA and normalization of K. There were no significant
differences between DM/CAP and DM/TRX rats in any param-
eter measured.
Long-term studies
As shown in Figure 2, stable moderate hyperglycemia was
maintained in the three diabetic groups, and blood pressures
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Table 1. Plasma renin concentration at 6 to 10 weeks of diabetes
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Table 2. Systemic and whole kidney parameters at 6 to 10 weeks of diabetes
Body wt LKW BG
mg/d!
HbAIC
%
Hct
vol/dI
AP
mm Hg
GFR
mi/mm
Plasma
Na K
mF2q/literGroup g
C 262 8 0.95 0.04 88 3 5.2 0.4 46 I 114 3 1.08 0.05 — —
(N = 8)
DM 275 7 1.21 0.osa 286 ioa 10.7 0.4a 48 I 117 3 1.69 0.08a 139 3 4.6 03
(N = 8)
DM/CAP 269 6 1.24 O.O4 351 16a.b 12.8 05a.b 4 b 98 3a.b 1.39 0.08 135 3 5.3 0.2
(N=8)
DM/TRX 270 5 1.23 0.05a 336 9a.b 10.7 0.4C 104 3b 1.54 0.07a 140 2 3.4 02b,c
(N= 11)
Abbreviations are: LKW, left kidney weight; HbA,, glycosylated hemoglobin; Hct, hematocrit; AP, mean arterial pressure; GFR, glomerular
filtration rate. Other abbreviations as in Table I. Values are means SEM. Normal values in this laboratory: Na, 143 2; K, 4.0 0.2.
a P < 0.05 vs. C
b P < 0.05 vs. DM
c P < 0.05 vs. DM/CAP
Table 3. Glomerular hemodynamics at 6 to 10 weeks of diabetes
Group
EMCPP
ni/mm SNFF
tTh
'eA
ni/mm
GC T 1E
mm Hg
C (N = 8) 42 3 0.29 0,02 146 12 48 1 14 0.3 18 1 34 1
DM (N = 8) 66 a 0.31 0.01 219 I9 64 2 13 0.4 18 1 51 2
DM/CAP (N =
DM/TRX (N = 8)11)
61 563 4 0.27 0.010.28 0,02 233 l9229 l4 47 1"49 1b 13 0.413 1 2219 11 3436 2"
Abbreviations used in this table: SN, single nephron; GFR, glomerular filtration rate; FF, filtration fraction; QA. glomerular capillary plasma flow
rate; P0, mean glomerular capillary hydraulic pressure; T' mean proximal tubule hydraulic pressure; P, mean efferent arteriolar hydraulic
pressure; F, mean glomerular transcapillary hydraulic pressure gradient; RA, RE and RT, aft'erent, efferent, and total (RA + RE) arteriolar
resistances; CA and CE, aff'erent and efferent arteriolar plasma protein concentrations; IDA and 1T, afferent and efferent arteriolar colloid osmotic
pressures; K1, glomerular capillary ultrafiltration coefficient; other abbreviations are in Table 1. Values are means SEM.
a P < 0.05 vs. C
b P < 0.05 vs. DM
Table 3. Continued
RA RE RT
x1O'°dyne sec cm5
RA/RT CA
gld!
CE IDA 1TE
mm Hg
K1
ni/(sec. mm Hg)
1.98 0.23 1.03 0.06 3.01 0.29 0.65 0.02 5.4 0.1 7.7 0.2 17 I 30 1 0.080 0.008
1.03 0.08a 1.09 0.11 2.12 0.17a 0.49 0.0 5.3 0.1 7.7 0.2 17 1 30 2 0.043 0.005
1.02 0.07a 0.63 1.65 0.l2a 0.62 0.01" 5.3 0.2 7.3 0.3 17 1 28 2 0.092 0.017
1.08 0.06a 0.71 004a.b 1.79 0.06 0.60 0.02" 5,4 0.1 7.5 0.2 18 1 29 1 0.113 0.022"
were maintained slightly lower in the groups receiving antihy-
pertensive treatment. Final determinations of SBP, body wt,
LKW, BG, and HbAIC are summarized in Table 4. Systolic
blood pressures remained slightly elevated in DM rats, and
comparably reduced in DM/CAP and DM/TRX rats. Body
weights in all diabetic groups were comparable, though lower
than those in C rats. Increased kidney weight was present in
DM rats, but limited to intermediate values in both treated
groups. Values for BG and HbAIC were comparably elevated in
all diabetic groups. Despite equivalent hyperglycemia and
blood pressure, and comparable hemodynamics early in the
course of diabetes, the long-term outcomes in the two treated
groups differed substantially. Serial values for UaIbV are de-
picted in Figure 3, and final values in Table 4. Non-diabetic C
rats exhibited minimal UaIbV early in life, but, as in previous
studies [6, 141, developed a modest degree of age-related
urinary albumin loss during the latter months of the study.
Diabetic rats receiving only insulin exhibited significant eleva-
tions in UalbV as early as one month after induction of diabetes,
and UA,bV increased markedly over time. During the first half
year of diabetes, values for UalbV remained in the normal range
in rats receiving CAP and TRX; thereafter, values in DM/TRX
rats rose substantially, eventually to values approaching those
in DM rats. By the final determination, values in DMJTRX rats
were still significantly lower than those in DM rats, but numer-
ically higher than those in C rats. In contrast, after 16 months of
diabetes, values in DMJCAP rats remained significantly lower
than those in all other groups, including even the aging non-
diabetic C rats.
Structural changes
Qualitatively, all diabetic groups exhibited identical changes
in the thick ascending portion of Henle's loop and distal
convoluted tubules. Areas of tubular atrophy and interstitial
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Table 4. Systemic and renal parameters at 70 weeks of diabetes
SBP
mm Hg
Body wt LKW BG
mg/d!
HbAIC
%
UaIbV
mg/day
FGS
%
V
X JOm3g
C 126 3 430 6 1.99 0.04 87 5 5.9 0.1 14 3 1.4 0.5 2.477 0.086
(N = 15)
DM 145 4' 310 ii" 2.38 009b 306 17b 12.0 05b 59 8b l2.0 2,2b 2.623 0.074
(N = 14)
DM/CAP 124 5C 325 9b 2.23 0.14 325 8b 11.4 0,8b 3 0.4 O.11C 2.127 0.l36c
(N = 10)
DM/TRX 115 4C 327 12b 2.15 0.08 307 20b 10.4 04b.c 36 11c,d 4.0 1,3b 2,074 0111b,c
(N = 12)
Abbreviations are: UajbV, 24-hr urinary albumin excretion rate; FGS, focal glomerular sclerosis; SBP, systolic blood pressure; V0. mean
glomerular volume; other abbreviations as in Tables I and 2. Values are means SEM.
a N = 14 (C), 11 (DM), 8 (DM/CAP), 10 (DM/TRX)b P < 0.05 vs. C
p < 0.05 vs. DM
d P < 0.05 vs. DM/CAP
fibrosis were roughly proportional to the degree of glomerular
involvement. Ultrastructural examination of randomly selected
glomeruli (3/animal) revealed mild increases in the thickness of
the glomerular basement membrane in all diabetic groups, as
compared to the nondiabetic control rats. Differences in gb-
merular basement membrane width between diabetic groups
were not readily apparent from this qualitative assessment.
Representative structural alterations in glomeruli from DM
and DM/CAP rats are illustrated in Figure 4. The extent of focal
and segmental gbomerular sclerosis corresponded well with
albuminuria values (Table 4). Non-diabetic C rats exhibited
modest values for glomerular sclerosis, averaging 1.4 0.5% of
gbomeruli (Fig. 5). The diabetic state was associated with
marked glomerular injury, with sclerosis involving 12.0 0.6%
of glomeruli in DM rats (P < 0.05 vs. all other groups). As in
previous studies using CEI therapy in diabetic rats [6], sclerosis
was strikingly limited in DMICAP rats, with the mean value (0.4
0.1%) being significantly lower than all other groups, includ-
ing the aging non-diabetic C rats. In contrast, despite equivalent
blood glucose and systemic blood pressure levels, morphologic
assessment in DMITRX rats demonstrated substantially less
protection. Although values for glomerular sclerosis in this
group (4.0 1.3%) were lower than those seen in the DM rats,
they were substantially higher than those in either C or DM1
CAP rats. Thus, both CAP and TRX conferred structural
protection as compared to the DM rats, but the degree of
DM/CAP protection afforded by captopril was clearly superior to that
afforded by TRX.
A potential risk factor for development of glomerular sclero-
sis which has recently received considerable attention is in-
creased glomerular volume [34—37]. Values for mean glomerular
volume (V0) in the four groups are depicted in Table 4.
Absolute values in all groups exceeded those determined in this
laboratory in younger Munich-Wistar rats [34]. Values in the C
and DM rats were similar. Both CAP and TRX limited glomer-
ular volumes to values significantly lower than those in DM
rats.
Late micropuncture measurements
Changes in glycemic control or systemic blood pressure
control could not be invoked to explain the late development of
injury in the DM/TRX rats. To further evaluate the mechanisms
which might underlie this apparent late treatment failure, mea-
surements of P0c were performed in some of the rats at the end
of the 70 week study, prior to sacrifice for morphologic exam-
ination. DM/CAP rats (N = 4) exhibited continued control of
glomerular hypertension, with values for P0c averaging 46 1
(range, 45.0 to 47.2 mm Hg). In contrast, though studies at 6 to
10 weeks had demonstrated control of glomerular hypertension
in DM/TRX rats, this effect was no longer present, with values
for P0C at 70 weeks now averaging 56 2 (range, 53.5 to 60.0
mm Hg, N = 4, P < 0.002 vs. DM/CAP). In these late studies,
values for RA were similar in the DMICAP and DM/TRX
groups, averaging 0.62 0.07 and 0.95 0.24 x 10'°
dyn sec cm5, respectively. However, values for RE were
p0
>30
DM
20
DM/TRX
10
4 12
C
20 28 36 44 52 60 68
Time, weeks of diabetes
Fig. 3. Albuminuria. Serial values for 24-hr urinary albumin excretion
(UaIbV) in non-diabetic control rats (C), diabetic rats (DM), and diabetic
rats treated with captopril (DM/CAP) or triple therapy (DM/TRX).
Non-diabetic C rats exhibited a slight increase in UaibV associated with
normal aging. In DM rats, UalbV values were significantly higher than
those in C rats at all time points. In DM/TRX rats, values for UaIbV
were near normal early in the course, but thereafter escalated; values
were significantly lower than those in DM rats starting at wk 20. Values
in DM/CAP rats were limited to the normal range throughout the study,
being significantly lower than those in both DM and DM/TRX rats at all
time points, and significantly lower than those in C rats after 60 weeks.
Values are means 5EM; N as per Fig. I.
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Fig. 4. Glomerular lesions. (A) Characteristic glomerular lesion from a DM rat, exhibiting segmental glomerular sclerosis and hyalin accumulation
(arrows) affecting approximately 30% of the tuft area. (B) In comparison, the majority ofglomeruli from DM/CAP rats were structurally intact.(Toluidine blue on I m thick epoxy sections, x 360).
significantly lower in DM/CAP than in DM/TRX rats, averaging
0.40 0.03 and 1.02 0.12 x 10'° dyn sec cm5, respec-
tively (P < 0.02). These results suggest that despite continued
systemic blood pressure control with TRX, long-term TRX
therapy in these rats was associated with escape from glomer-
ular capillary hypertensive control, at a time point not directly
ascertained in this study.
Discussion
In the moderately hyperglycemic normotensive diabetic rats,
both monotherapy with captopril, and triple therapy with reser-
pine, hydralazine and hydrochlorothiazide, were effective in
modestly but significantly reducing the systemic arterial pres-
sure. Using tail cuff measurements of awake systolic blood
pressure, DM rats exhibited slightly higher values than did
non-diabetic controls, whereas mean arterial pressures by di-
rect femoral artery manometry were similar in DM and C rats.
The phenomenon of hypertension by tail cuff, with normoten-
sion by direct measurement, has been noted previously and
attributed to stress of prewarming and restraint, as well as to
reduction of skeletal muscle mass and increased fibrous tissue
in the tails of streptozotocin-diabetic rats [38]. Diurnal variabil-
ity in blood pressure control cannot be excluded; nevertheless,
the observed blood pressure values were quite consistent in any
given animal from month to month.
When studied early in the course of diabetes, the effects of
captopril and TRX on glomerular hemodynamics were compa-
rable to one another, as well as to those previously noted in
diabetic rats treated with the CEI enalapril [6]. As in previous
studies [4—6], the moderately hyperglycemic diabetic rats ex-
hibited single nephron hyperfiltration and hyperperfusion. The
groups treated with antihypertensive therapy exhibited lower
blood pressures but similar degrees of increased kidney weight,
hyperliltration and hyperperfusion when compared to the DM
rats. In all diabetic groups, values for RA were substantially
reduced as compared to the nondiabetic C rats. In the DM rats
receiving no therapy other than insulin, the ratio of RA/RT was
substantially reduced, allowing enhanced transmission of sys-
temic pressures to the glomerular capillary network. Both CAP
and TRX were associated with comparable reductions of RA as
compared to C rats; however, they also produced a concomi-
tant reduction in RE, which offset the reduction in RA, thereby
reducing P0 to normal levels.
The effects of CAP therapy on intraglomerular hemodynam-
ics are fully consistent with inhibition of angiotensin Il-induced
15
CA
Fig. 5. Focal glomerular sclerosis. Mean values for focal glomerular
sclerosis in non-diabetic control rats (C), diabetic rats (DM), and
diabetic rats treated with captopril (DM/CAP) or triple therapy (DM1
TRX). Values are means 5EM; N as per Table 4; p < 0.05 vs. C, tp
<0.05 vs. DM; P < 0.05 vs. DM/CAP.
C DM OM/CAP DM/TRX
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enhancement of efferent arteriolar tone, as well as with numer-
ous previous studies demonstrating efferent arteriolar relax-
ation with these agents in various experimental models [6,
9—14]. The intraglomerular hemodynamic consequences of TRX
in this model were more difficult to predict, since TRX lowers
RE in some models [13, 171 but not in others [10, 18, 19].
Activity of the systemic blood renin-angiotensin system (RAS)
does not appear to be a critical factor, since this regimen lowers
RE in some models of low renin hypertension, such as the
uninephrectomized SHR [13], but not in others, including the
partially nephrectomized rat [10] and mine ralocorticoid-salt
hypertension [18]. Of interest, this regimen raises PRC and fails
to lower RE and P0 in the partially nephrectomized rat [10],
which is characterized by plasma volume expansion [39]. In the
moderately hyperglycemic diabetic rat, which is also character-
ized by plasma volume expansion [40] and low !RC values, this
regimen also raises PRC, but lowers RE and GC early in the
course of diabetes. Thus, plasma volume and PRC do not
appear to be consistent predictors of the glomerular hemody-
namic consequences of this vasodilator/diuretic regimen. These
observations are consistent with the growing body of evidence
which suggests that the tissue (including intrarenal) RAS may
be a more important contributor to systemic and local vascular
hemodynamic regulation than is the plasma RAS [41].
During the early months of diabetes, control of systemic
blood pressure with either TRX or captopril markedly limited
the development of albuminuria. Thereafter, while UalbV val-
ues in DM/CAP rats remained at levels which were eventually
even lower than those in aging non-diabetic C rats, mean values
in DM/TRX rats escalated in dramatic fashion. These results
are reminiscent of those previously noted in another two-kidney
low-renin model, the spontaneously hypertensive rat (SHR), in
which TRX was felt to prevent [42], but later found only to
delay [43], the development of glomerular injury. Of particular
importance is the observation that after 70 weeks of diabetes,
captopril afforded continued control of glomerular capillary
hypertension, as previously noted with enalapril therapy in a
post-nephrotic model of glomerular injury in rats followed for a
comparable period of time [14]. In contrast, despite continuing
control of systemic hypertension, the aging DM/TRX rats had
escaped from GC control, and exhibited a concurrent rise in
albuminuria. The possibility that glomerular injury may have
influenced hemodynamic findings in the DM/TRX rats studied
late in the course cannot be totally excluded. However, values
for UaIbV in the animals examined were still low (< 10 mg/d) in
three animals, and elevated (26 mg/day) in only one. Accord-
ingly, it seems unlikely that glomerular injury was sufficient to
explain the glomerular hypertension found in all of these
animals.
As in previous studies with dietary protein restriction [5] and
CE! therapy [6] in this model, development of albuminuria
clearly had no relation to metabolic control; values for BG were
continuously comparable in all diabetic groups, and values for
HbAIC were highest in the DM/CAP rats, which consistently
exhibited the lowest Ua(bV levels.
Changes in glomerular volume were also not helpful in
differentiating between the outcomes of the treated groups,
though the reduction in glomerular volume may help to explain
the protection afforded by both regimens as compared to the
DM rats. Increased glomerular volume has been noted previ-
ously in diabetes [35, 44] as well as in other experimental
models characterized by hyperfiltration and particularly by
glomerular hypertension [9]. When the adaptive increase in
glomerular volume is prevented by dietary protein restriction in
diabetic rats [35], by CE! therapy in rats with renal ablation [9],
in adriamycin-induced proteinuria [34], or in a model of renal
ablation with contralateral ureteral diversion [36], glomerular
sclerosis is also limited. In the present study, both antihyper-
tensive regimens limited glomerular volumes to the same ex-
tent. For the DM/CAP group, in which GCwas also limited to
normal values, glomerular injury was virtually non-existent. In
the DM/TRX rats, lack of control of P (at least in the late
stages) appeared to be the more significant predictor of glomer-
ular injury. Thus, changes in glomerular volume alone cannot
fully explain the development of glomerular injury in this
model.
The design of this study did not allow documentation of the
point at which control of glomerular hypertension in DM/TRX
rats was lost, though examination of the albuminuria curves
may suggest that albuminuria, perhaps reflecting glomerular
pressure, began to rise sharply after about six or seven months
of diabetes (Fig. 3). However, evidence suggests that the levels
of putative vasoactive mediators may change during the course
of long-term diabetes. Early diabetes is characterized by rela-
tively low values for plasma renin activity (PRA) and plasma
All levels, with normal levels of inactive renin and serum
converting enzyme, and appropriate suppression of PRA with
increased blood pressure or sodium intake [45—50]. However,
later in the course, after albuminuna supervenes, values for
PRA and inactive renin rise [46, 47], and converting enzyme
levels tend to increase with duration of streptozotocin diabetes
[51]. Lower doses of exogenous A!! are required to raise blood
pressure, and suppression of PRA with increased blood pres-
sure or sodium intake is impaired [45]. These observations
suggest enhanced vascular responsiveness to vasoactive stim-
uli, including All, in the presence of albuminuria and diabetic
glomerulopathy. In addition, it has been recently reported that
the number of glomerular A!! binding sites in the rat increases
with advancing age [52]. In the present study, such alterations
in the renin-angiotensin system over time may well have
contributed to the altered glomerular hemodynamic response in
the DM/TRX rats. Similarly, local prostaglandin levels and
circulating levels of atrial peptides also undergo changes from
normal in diabetes [40, 53] as well as during the course of the
disease [53], and may also contribute to sequential changes in
glomerular hemodynamics over the extended course of this
study. Clearly, further studies of sequential alterations in vaso-
regulatory factors in diabetes are required to understand the
natural history of this disease, as well as the long-term conse-
quences of therapy.
Results in the DM/CAP rats herein confirm those noted in this
laboratory with the CE! enalapril in this model [6]. In other
studies in which glomerular hemodynamics were not measured,
CE! therapy limited albuminuria, mesangial expansion, and
glomerular basement membrane thickening in the diabetic SHR
[54], and reduced blood pressure, filtration fraction (presum-
ably reflecting P0), and proteinuria in uninephrectomized
diabetic rats [55]. In relatively short-term studies, administra-
tion of TRX lowered blood pressure and limited injury in the
diabetic SHR [56, 57]. Bank and coworkers [571 reported that
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moderately hyperglycemic diabetic SHR and Wistar Kyoto
(WKY) rats both exhibited increases in SNGFR, QA and P0c as
compared to nondiabetic controls, with values for GC being
slightly though significantly higher in the diabetic SHR than the
diabetic WKY. Unfortunately, that study was terminated prior
to the development of proteinuria or substantial glomerular
injury. At the time of sacrifice, mesangial expansion was
comparable in the diabetic SHR and WKY, and ameliorated in
a third group of diabetic SHR in which antihypertensive therapy
lowered GC toward, but not to the normal range. Thus, within
the scope of that study [57], both diabetic groups exhibited
glomerular hypertension and mesangial expansion, while the
group receiving TRX exhibited lower values for both P and
mesangial expansion. These results are comparable to those
seen in the current study, where TRX lowered GC and UajbV
during the early months of diabetes; however, the effects of this
regimen on long-term development of albuminuria and glomer-
ular obsolescence in the diabetic SHR remain to be examined.
Clinical studies spanning as many as six years have estab-
lished that antihypertensive therapy started relatively early in
the course of diabetic nephropathy slows the progression of
renal disease [15, 16]. Typically, the antihypertensive regimens
have consisted of a diuretic, a vasodilator, and a beta-blocker,
and it might be speculated that the latter would tend to suppress
the RAS. However, while these studies are encouraging, they
have yet to reach sufficient duration to establish whether
diabetic nephropathy is truly prevented, rather than delayed. Of
note, diuretic therapy (which would be expected to stimulate
the RAS) has recently been correlated with accelerated devel-
opment of clinical diabetic glomerulopathy [58]. In patients with
advanced diabetic nephropathy, administration of captopril has
been reported to markedly slow the progression of renal insuf-
ficiency [59], though only comparison to other reported studies
could be made. To date there are no adequate studies compar-
ing CEI to alternative antihypertensive regimens in diabetic
patients. However, in patients with non-diabetic renal disease,
several recent preliminary short-term studies suggest that CE!
may be superior to conventional combination regimens in
reducing proteinuria [20—22], and perhaps in slowing disease
progression. That the beneficial effects of CE! are not entirely
due to reduction in systemic pressure is indicated by observa-
tions that CE! therapy reduces UaIbV in the absence of sub-
stantial changes in either blood pressure or GFR, suggesting
that the reduction in Ua}bV excretion may be a direct conse-
quence of control of P0c [60—62].
In summary, the long-term consequences of captopril and
TRX were compared in moderately hyperglycemic diabetic
rats. Blood pressure was modestly and comparably reduced in
both treated groups as compared to the normotensive diabetic
rats receiving only insulin. Early in diabetes, CAP and TRX
were equally effective in selectively controlling glomerular
hypertension, without affecting SNGFR or QA. At this time,
both regimens were effective in preventing albuminuria, though
captopnl appeared slightly more efficacious than TRX. There-
after, TRX rats rapidly developed albuminuria, and despite
continued control of systemic blood pressure, this group devel-
oped glomerular hypertension and moderate glomerular injury.
Captopril therapy afforded continued control of systemic and
glomerular hypertension, and prevented the development of
glomerular injury. These studies lend further support to the
previous observations [5, 6] that hemodynamic rather than
metabolic factors predominate in the pathogenesis of glomeru-
lar injury in the diabetic rat. Furthermore, these studies confirm
the clinical observations that antihypertensive therapy slows
the progression of diabetic renal disease, but also indicate that
captopril is more effective than TRX in preventing the devel-
opment of glomerulopathy in experimental diabetes. These
observations underscore the need for clinical studies to ascer-
tain whether agents such as CE!, which offer continuing control
of glomerular hypertension in the rat, will provide superior
protection against the devastating glomerular and extrarenal
microvascular complications of the diabetic state.
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